Chart pattern: Inverse Head and Shoulders (weekly)
▲ Broken out
Broke on Oct 23, 2026 · measured target $32.52 (+4%). Details →
Oct 29, 6:50 AM ET
Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million, up 1.7% from $492.9 million a year earlier, and adjusted EPS of $0.72 versus $0.67. GAAP net income fell to $47.0 million, or $0.59 per diluted share, from $71.7 million, or $0.84, and adjusted EBITDA declined to $85.5 million from $87.3 million. The company also projects full-year 2026 adjusted EBITDA of $290 million to $300 million.
- Q3 net revenue $501.4 million vs. $492.9 million in Q3 2025, up 1.7%
- Q3 net income $47.0 million ($0.59 diluted EPS) vs. $71.7 million ($0.84), including a $20.9 million investment gain in the prior-year quarter
- Q3 adjusted EPS $0.72 vs. $0.67; adjusted EBITDA $85.5 million vs. $87.3 million
- Full-year 2026 adjusted EBITDA outlook of $290 million to $300 million
Read the filing on SEC.gov ↗
Aug 4, 6:50 AM ET
Pediatrix Medical Group reported second-quarter 2026 revenue of $487.8 million, up 4.0% from a year earlier, and net income of $39.8 million, or $0.49 per diluted share, compared with $0.46 in the prior-year quarter. The company reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, though same-unit patient volume fell 2.1%.
- Q2 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier
- Net income of $39.8 million, or $0.49 per diluted share, vs. $0.46 in Q2 2025
- Adjusted EPS of $0.63 vs. $0.53; Adjusted EBITDA of $76.4 million vs. $73.2 million
- Full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million reaffirmed; same-unit volume down 2.1%
Read the filing on SEC.gov ↗
Jul 24, 5:00 PM ET
Pediatrix Medical Group said its General Counsel, Chief Administrative Officer and Secretary, Mary Ann E. Moore, will serve in an advisory role until October 31, 2026, when she leaves the company. The company also named David Haddock as Executive Vice President, General Counsel and Secretary, a senior legal role that shareholders may watch as the transition takes effect.
- Mary Ann E. Moore's transition is a termination without cause under her employment agreement, with benefits specified in that agreement.
- Moore will serve in an advisory role until October 31, 2026, under a Separation Agreement signed July 21, 2026.
- David Haddock was appointed Executive Vice President, General Counsel and Secretary.
- The company first reported the planned transition on May 1, 2026.
Read the filing on SEC.gov ↗
Jul 15, 7:00 AM ET
Pediatrix Medical Group said in a July 15, 2026 update on its second quarter that its payor mix stayed stable and in line with recent trends and internal expectations, and it has not seen material changes in other net revenue trends. The company reaffirmed its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million, and it did not report second quarter financial results in this filing. Full results are due in a release on August 4, 2026.
- Full year 2026 Adjusted EBITDA outlook reaffirmed at $280 million to $300 million
- Second quarter payor mix stable and unchanged relative to recent historical trends and internal expectations
- Company says it has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector
- Investor conference call and detailed results release scheduled for August 4, 2026, at 9:00 a.m. ET
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.